In late October, the FDA approved the first biosimilar to ustekinumab to treat patients with psoriasis, psoriatic arthritis and other conditions. Ustekinumab-auub is expected to be available in the U.S. by 2025.
Search results for: pediatric
Updates from AMA House of Delegates 2023 Interim Meeting
Last month, the ACR’s delegation to the AMA House of Delegates discussed and advanced resolutions to address specialty workforce shortages, payment reform and access to care.
Heterogeneity in Lupus: Lessons from the Autoimmune Centers of Excellence
SAN DIEGO—The Autoimmunity Centers of Excellence (ACE) are a cooperative group funded by the National Institute of Allergy and Infectious Diseases (NIAID) that conduct basic and clinical research on autoimmune diseases.1 ACEs focus on treatment and prevention strategies that induce immune tolerance or modulate the immune system. The goal is to facilitate collaboration across clinicians…
Striving for Equity
SAN DIEGO—At ACR Convergence 2023, panelists provided guidance for reducing disparities and improving health equity for patients who are negatively impacted by social determinants of health.
Where Viral Infections Meet Rheumatic Disease
SAN DIEGO—Viral infections are a common cause of acute arthritis and, in general, tend to be short lived and are not usually associated with significant articular inflammation. Due to the prevalence of various viral infections across the globe, any patient with signs of early inflammatory arthritis (i.e., symptoms that have not yet lasted six weeks) should be evaluated for a possible infectious etiology, said Dr. Leonard Calabrese in the Review Course at ACR Convergence 2023.
The ACR Thanks Members for Supporting RheumPAC During Matching Campaign
This year’s matching campaign raised more than $20,000 from ACR and ARP members and staff and another $7,300 from volunteer leaders.
Life with Arthritis: Kaleb Michaud, PhD, Shares His Story
SAN DIEGO—“I’m going to get personal,” said Kaleb Michaud, PhD, in the ARP Distinguished Lecture at ACR Convergence 2023. When he was 3 years old, the young Kaleb was diagnosed him with juvenile rheumatoid arthritis (JRA).
Growing Up
SAN DIEGO—In the pre-ACR Convergence 2023 Review Course, Rebecca Sadun, MD, PhD, assistant professor in medicine and pediatrics, Duke University School of Medicine, Durham, N.C., focused on transitions from pediatric to adult rheumatology care for patients with juvenile idiopathic arthritis (JIA).
President’s Perspective: Deborah Dyett Desir, MD, Assumes ACR Presidency
Deborah Dyett Desir, MD is the 87th ACR president and the first Black person elected to the position. In conversation with The Rheumatologist, this profile follows her career from academic research to private practice to Yale faculty & the ACR presidency.
ARP Welcomes a New President: A Conversation with Aileen Ledingham, PT, MS, PhD
With roots in physical therapy & rehabilitation research, Dr. Ledingham brings to the ARP a deep enthusiasm for volunteering & collaboration, as well as a commitment to building public knowledge about the field of rheumatology.
- « Previous Page
- 1
- …
- 23
- 24
- 25
- 26
- 27
- …
- 112
- Next Page »